Sage Therapeutics Stock Forecast, Price & News

17 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Sage Therapeutics in the last year. There are currently 10 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" Sage Therapeutics stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in SAGE, but not buy additional shares or sell existing shares.
View analyst ratings for Sage Therapeutics or view top-rated stocks.

Wall Street analysts have given Sage Therapeutics a "Hold" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Sage Therapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Sage Therapeutics is scheduled to release its next quarterly earnings announcement on Tuesday, August 3rd 2021.
View our earnings forecast for Sage Therapeutics.

Sage Therapeutics will be holding an earnings conference call on Tuesday, August 3rd at 8:00 AM Eastern. Interested parties can register for or listen to the call using this link.

Sage Therapeutics, Inc. (NASDAQ:SAGE) posted its quarterly earnings results on Tuesday, May, 4th. The biopharmaceutical company reported ($1.64) EPS for the quarter, topping the Zacks' consensus estimate of ($1.98) by $0.34. The biopharmaceutical company earned $1.58 million during the quarter, compared to analysts' expectations of $2.03 million. Sage Therapeutics had a net margin of 57.21% and a negative trailing twelve-month return on equity of 32.31%. The business's revenue for the quarter was down 30.8% compared to the same quarter last year. During the same period in the previous year, the firm earned ($2.44) earnings per share.
View Sage Therapeutics' earnings history.

Sage Therapeutics' stock was trading at $42.30 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, SAGE shares have increased by 5.4% and is now trading at $44.58.
View which stocks have been most impacted by COVID-19.

17 equities research analysts have issued 1-year price targets for Sage Therapeutics' stock. Their forecasts range from $62.00 to $102.00. On average, they anticipate Sage Therapeutics' stock price to reach $83.65 in the next year. This suggests a possible upside of 87.6% from the stock's current price.
View analysts' price targets for Sage Therapeutics or view top-rated stocks among Wall Street analysts.

Some companies that are related to Sage Therapeutics include Dr. Reddy's Laboratories (RDY), Jazz Pharmaceuticals (JAZZ), CureVac (CVAC), Mirati Therapeutics (MRTX), United Therapeutics (UTHR), BridgeBio Pharma (BBIO), Biohaven Pharmaceutical (BHVN), HUTCHMED (HCM), Arrowhead Pharmaceuticals (ARWR), Evotec (EVTCY), Ascendis Pharma A/S (ASND), Perrigo (PRGO), Legend Biotech (LEGN), I-Mab (IMAB) and Sarepta Therapeutics (SRPT).
View all of SAGE's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Sage Therapeutics investors own include NVIDIA (NVDA), AbbVie (ABBV), Micron Technology (MU), Alibaba Group (BABA), Advanced Micro Devices (AMD), Gilead Sciences (GILD), Netflix (NFLX), Roku (ROKU), QUALCOMM (QCOM) and Bristol-Myers Squibb (BMY).

Sage Therapeutics trades on the NASDAQ under the ticker symbol "SAGE."

Sage Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Pinnacle Associates Ltd. (0.13%), Alliancebernstein L.P. (0.04%), Cutler Group LP (0.00%), Ziegler Capital Management LLC (0.02%), State of Alaska Department of Revenue (0.02%) and Hillsdale Investment Management Inc. (0.01%). Company insiders that own Sage Therapeutics stock include Albert Robichaud, Barry E Greene, James M Frates and Jeffrey M Jonas.
View institutional ownership trends for Sage Therapeutics.

SAGE stock was sold by a variety of institutional investors in the last quarter, including Alliancebernstein L.P..
View insider buying and selling activity for Sage Therapeutics or view top insider-selling stocks.

SAGE stock was acquired by a variety of institutional investors in the last quarter, including Ziegler Capital Management LLC, Cutler Group LP, Hillsdale Investment Management Inc., Cooper Financial Group, State of Alaska Department of Revenue, Pinnacle Associates Ltd., and HighPoint Advisor Group LLC. Company insiders that have bought Sage Therapeutics stock in the last two years include Albert Robichaud, Barry E Greene, James M Frates, and Jeffrey M Jonas.
View insider buying and selling activity for Sage Therapeutics or or view top insider-buying stocks.

Shares of SAGE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of SAGE stock can currently be purchased for approximately $44.58.

Sage Therapeutics has a market capitalization of $2.61 billion and generates $1.11 billion in revenue each year. The biopharmaceutical company earns $606.07 million in net income (profit) each year or ($9.47) on an earnings per share basis.

Sage Therapeutics employs 298 workers across the globe.

The official website for Sage Therapeutics is www.sagerx.com.

Sage Therapeutics is headquartered at 215 FIRST STREET, CAMBRIDGE MA, 02142.

Sage Therapeutics' mailing address is 215 FIRST STREET, CAMBRIDGE MA, 02142. The biopharmaceutical company can be reached via phone at (617) 299-8380 or via email at [email protected]